

Disclosure Purpose: 21-16596

Summary of Interests

Entity	Type	Interest Held By
Bristol-Myers Squibb	Grant / Contract	Self
<i>Recipient Name:</i> Charalambos Andreadis <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Epizyme, Inc.,	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i>
Genentech	Employment	Spouse/Partner
<i>Title:</i> research scientist <i>Additional Information:</i> ended 2/18/2020		<i>Position Description:</i>
Incyte Corporation	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i>
Karyopharm Therapeutics	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i>
Kite Pharma, Inc.	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i>
Merck	Grant / Contract	Self
<i>Recipient Name:</i> Charalambos Andreadis <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Novartis	Grant / Contract	Self
<i>Recipient Name:</i> Charalambos Andreadis <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i>
TG therapeutics	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i>

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Novartis	Employment	Self
<i>Title:</i> Clinical Development Medical Director		<i>Position Description:</i> Clinical study medical directo
<i>Additional Information:</i>		
Novartis	Stock Option	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Novartis Pharmaceuticals Corporation	Employment	Self
<i>Title:</i> Principal Scientist <i>Additional Information:</i>	<i>Position Description:</i>	

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization	Type	Interest Held By
AbbVie	Travel	Self
<i>Location(s):</i> San Diego <i>Additional Information:</i>		<i>Purpose:</i> Congress
Amgen	Grant / Contract	Self
<i>Recipient Name:</i> IRCCS <i>Grant / Contract Description:</i> Research grant <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Celgene	Other	Self
<i>Category:</i> Other <i>Additional Information:</i>		<i>Description:</i> Scientific Advisory Board
Incyte Corporation	Other	Self
<i>Category:</i> Other <i>Additional Information:</i>		<i>Description:</i> Speaking engagement
Incyte Corporation	Other	Self
<i>Category:</i> Other <i>Additional Information:</i>		<i>Description:</i> Scientific Advisory Board
Incyte Corporation	Travel	Self
<i>Location(s):</i> Paris <i>Additional Information:</i>		<i>Purpose:</i> Congress
Kite Pharma, Inc.	Other	Self
<i>Category:</i> Other <i>Additional Information:</i>		<i>Description:</i> Scientific Advisory Board
Novartis	Other	Self
<i>Category:</i> Other <i>Additional Information:</i>		<i>Description:</i> Speaking engagement

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Bristol-Myers Squibb	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Advisory boards
Bristol-Myers Squibb	Travel	Self
<i>Location(s):</i> several in Europe and US <i>Additional Information:</i>		<i>Purpose:</i> hematology meetings, ASH, SEHH,EHA
Kite Pharma, Inc.	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Advisory board
Kite Pharma, Inc.	Travel	Self
<i>Location(s):</i> several in Europe and US <i>Additional Information:</i>		<i>Purpose:</i> hematology meetings, ASH, SEHH,EHA
Novartis	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> advisory boards
Novartis	Travel	Self
<i>Location(s):</i> several in Europe and US <i>Additional Information:</i>		<i>Purpose:</i> hematology meetings, ASH, SEHH,EHA

Additional Questions:

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
2. **What is the manuscript title?**
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization	Type	Interest Held By
Bristol Myers Squibb Company <i>Category:</i> Consultant <i>Additional Information:</i> Also participate in speakers bureau outside this work	Consultant	Self
CRISPR Therapeutics <i>Category:</i> Consultant <i>Additional Information:</i> Also serve as clinical investigator and steering committee for clinical trials	Consultant	Self
Kite Pharma, Inc. <i>Category:</i> Consultant <i>Additional Information:</i> Serve as clinical investigator on clinical trials and participate on company-sponsored speakers bureau	Consultant	Self
Novartis <i>Category:</i> Consultant <i>Additional Information:</i> Serve as investigator and steering committees for clinical trials	Consultant	Self
Sana Biotechnology <i>Category:</i> Consultant <i>Additional Information:</i>	Consultant	Self

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
- Are you the corresponding author?**
Yes.
 - Please list the other authors' names here.**
Michael Dickinson, Duncan Purtill, Pere Barba, Armando Santoro, Nada Hamad, Koji Kato, Anna Sureda, Richard Greil, Catherine Thieblemont, Franck Morschhauser, Martin Janz, Ian Flinn, Werner Rabitsch, Yok Lam Kwong, Marie José Kersten, Monique C. Minnema, Harald Holte, Esther Hian Li Chan, Joaquin Martinez-Lopez, Antonia M.S. Mueller, Richard T. Maziarz, Joseph P. McGuirk, Emmanuel Bachy, Steven Le Gouill, Martin Dreyling, Hideo Harigae, David Bond, Charalambos Andreadis, Peter McSweeney, Mohamed Kharfan-Dabaja, Simon Newsome, Evgeny Degtyarev, Rakesh Awasthi, Christopher del Corral, Giovanna Andreola, Aisha Masood, Stephen J. Schuster, Ulrich Jaeger, Peter Borchmann, Jason R. Westin

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Kite Pharma, Inc.	Other	Self
<i>Category:</i> Other <i>Additional Information:</i>		<i>Description:</i> Scientific advisory board
Seagen Inc.	Other	Self
<i>Category:</i> Other <i>Additional Information:</i>		<i>Description:</i> Scientific advisory board

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Novartis	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i>

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AstraZeneca	Other	Self
<i>Category: Other</i> <i>Additional Information:</i>		<i>Description: Ad board/talks</i>
Novartis	Other	Self
<i>Category: Other</i> <i>Additional Information:</i>		<i>Description: Speaking engagement/Ad Board</i>

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Novartis	Employment	Self
<i>Title:</i> Director <i>Additional Information:</i>		<i>Position Description:</i> Biostatistics
Novartis	Stock	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Novartis	Employment	Self
<i>Title:</i> Associate Clinical Development Director		<i>Position Description:</i> Responsible for scientific and clinical strategy related to drug development
<i>Additional Information:</i>		
Novartis	Stock	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Bristol-Myers Squibb	Grant / Contract	Other - Employing Institution
<i>Recipient Name:</i> Michael Dickinson <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Bristol-Myers Squibb	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Advisory Board
Gilead Sciences	Grant / Contract	Other - Employing institution
<i>Recipient Name:</i> Peter MacCallum Cancer Centre <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Novartis	Grant / Contract	Other - Hospital
<i>Recipient Name:</i> Peter MacCallum Cancer Centre <i>Grant / Contract Description:</i> Research Funding <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Novartis	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i>
Novartis	Other	Self
<i>Category:</i> Other <i>Additional Information:</i>		<i>Description:</i> Advisory Board
Roche	Grant / Contract	Other - Employing organisation
<i>Recipient Name:</i> Peter MacCallum Cancer Centre <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Roche	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i>

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AbbVie	Grant / Contract	Self
<i>Recipient Name:</i> Martin Dreyling <i>Grant / Contract Description:</i> clinical study <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Amgen	Grant / Contract	Self
<i>Recipient Name:</i> Martin Dreyling <i>Grant / Contract Description:</i> speaker honoraria <i>Additional Information:</i>		<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Other - speaker honoraria
AstraZeneca	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> scientific advisory board
Bayer	Grant / Contract	Self
<i>Recipient Name:</i> Martin Dreyling <i>Grant / Contract Description:</i> clinical trial <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Bayer	Other	Self
<i>Category:</i> Other <i>Additional Information:</i>		<i>Description:</i> speaker honoraria
Bayer	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> scientific advisory board
BeiGene Switzerland GmbH	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> scientific advisory board
Bristol-Myers Squibb	Grant / Contract	Self
<i>Recipient Name:</i> Martin Dreyling <i>Grant / Contract Description:</i> clinical study <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Bristol-Myers Squibb	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> scientific advisory board
Bristol-Myers Squibb	Other	Self
<i>Category:</i> Other <i>Additional Information:</i>		<i>Description:</i> speaker honoraria
Eli Lilly and Company	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> scientific advisory board
F. Hoffmann-La Roche	Grant / Contract	Self
<i>Recipient Name:</i> Martin Dreyling <i>Grant / Contract Description:</i> clinical study <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
F. Hoffmann-La Roche	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> scientific advisory board

F. Hoffmann-La Roche	Other	Self
<i>Category: Other</i>		<i>Description: speaker honoraria</i>
<i>Additional Information:</i>		
Gilead Sciences	Grant / Contract	Self
<i>Recipient Name: Martin Dreyling</i>		<i>Recipient Type: Institution</i>
<i>Grant / Contract Description: clinical study</i>		<i>Grant / Contract Purpose: Research</i>
<i>Additional Information:</i>		
Gilead Sciences	Other	Self
<i>Category: Other</i>		<i>Description: scientific advisory board</i>
<i>Additional Information:</i>		
Gilead Sciences	Other	Self
<i>Category: Other</i>		<i>Description: Speaker honoraria</i>
<i>Additional Information:</i>		
Incyte Corporation	Other	Self
<i>Category: Other</i>		<i>Description: speaker honoraria</i>
<i>Additional Information:</i>		
Incyte Corporation	Consultant	Self
<i>Category: Consultant</i>		<i>Description: scientific advisory board</i>
<i>Additional Information:</i>		
Janssen Biotech	Grant / Contract	Self
<i>Recipient Name: Martin Dreyling</i>		<i>Recipient Type: Institution</i>
<i>Grant / Contract Description: clinical study</i>		<i>Grant / Contract Purpose: Research</i>
<i>Additional Information:</i>		
Janssen Biotech	Other	Self
<i>Category: Other</i>		<i>Description: speaker honoraria</i>
<i>Additional Information:</i>		
Janssen Biotech	Consultant	Self
<i>Category: Consultant</i>		<i>Description: scientific advisory board</i>
<i>Additional Information:</i>		
Novartis	Consultant	Self
<i>Category: Consultant</i>		<i>Description: scientific advisory board</i>
<i>Additional Information:</i>		
Novartis	Other	Self
<i>Category: Other</i>		<i>Description: speaker honoraria</i>
<i>Additional Information:</i>		

Additional Questions:

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
2. **What is the manuscript title?**
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AbbVie	Grant / Contract	Self
<i>Recipient Name:</i> SARAH CANNON RESEARCH INSTITUTE <i>Grant / Contract Description:</i> RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
AbbVie	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> Consulting paid to institution, Sarah Cannon Research Institute		<i>Description:</i> CONSULTANCY: ADVISORY BOARD OR STEERING COMMITTEE PAID TO INSTITUTION
ACERTA PHARMACEUTICALS	Grant / Contract	Self
<i>Recipient Name:</i> SARAH CANNON RESEARCH INSTITUTE <i>Grant / Contract Description:</i> RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Agios Pharmaceuticals, Inc.	Grant / Contract	Self
<i>Recipient Name:</i> SARAH CANNON RESEARCH INSTITUTE <i>Grant / Contract Description:</i> RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
ARQULE	Grant / Contract	Self
<i>Recipient Name:</i> SARAH CANNON RESEARCH INSTITUTE <i>Grant / Contract Description:</i> RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
AstraZeneca	Grant / Contract	Self
<i>Recipient Name:</i> SARAH CANNON RESEARCH INSTITUTE <i>Grant / Contract Description:</i> RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
AstraZeneca	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> All payments made to Sarah Cannon Research Institute, not to the physician		<i>Description:</i> All payments made to Sarah Cannon Research Institute, not to the physician
BEIGENE	Grant / Contract	Self
<i>Recipient Name:</i> SARAH CANNON RESEARCH INSTITUTE <i>Grant / Contract Description:</i> RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
BEIGENE	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> All payments made to Sarah Cannon Research Institute, not to the physician		<i>Description:</i> All payments made to Sarah Cannon Research Institute, not to the physician
Calithera Biosciences	Grant / Contract	Self
<i>Recipient Name:</i> Sarah Cannon Research Institute <i>Grant / Contract Description:</i> All payments made to Sarah Cannon Research Institute, not to the physician <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research <i>Additional Information:</i> All payments made to Sarah Cannon Research Institute, not to the physician
Celgene	Grant / Contract	Self
<i>Recipient Name:</i> SARAH CANNON RESEARCH INSTITUTE <i>Grant / Contract Description:</i> RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Century Therapeutics	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> All payments made to Sarah Cannon Research Institute, not to the physician		<i>Description:</i> All payments made to Sarah Cannon Research Institute, not to the physician

Constellation Pharmaceuticals	Grant / Contract	Self
<i>Recipient Name:</i> Sarah Cannon Research Institute <i>Grant / Contract Description:</i> All payments made to Sarah Cannon Research Institute, not to the physician		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research <i>Additional Information:</i> All payments made to Sarah Cannon Research Institute, not to the physician		
CURIS	Grant / Contract	Self
<i>Recipient Name:</i> SARAH CANNON RESEARCH INSTITUTE <i>Grant / Contract Description:</i> RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
F. HOFMAN-LA ROCHE LTD	Grant / Contract	Self
<i>Recipient Name:</i> SARAH CANNON RESEARCH INSTITUTE <i>Grant / Contract Description:</i> RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
F. HOFMAN-LA ROCHE LTD	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> Consulting payment made to institution, Sarah Cannon Research Institute		
<i>Description:</i> CONSULTING FOR ADVISORY BOARD OR STEERING COMMITTEE: PAYMNET MADE TO INSTITUTION		
FORMATHERAPEUTICS	Grant / Contract	Self
<i>Recipient Name:</i> SARAH CANNON RESEARCH INSTITUTE <i>Grant / Contract Description:</i> RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
FORTY SEVEN	Grant / Contract	Self
<i>Recipient Name:</i> SARAH CANNON RESEARCH INSTITUTE <i>Grant / Contract Description:</i> RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Genentech	Grant / Contract	Self
<i>Recipient Name:</i> SARAH CANNON RESEARCH INSTITUTE <i>Grant / Contract Description:</i> RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Genentech	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> All payments made to Sarah Cannon Research Institute, not to the physician		
<i>Description:</i> All payments made to Sarah Cannon Research Institute, not to the physician		
Genmab	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> All payments made to Sarah Cannon Research Institute, not to the physician		
<i>Description:</i> All payments made to Sarah Cannon Research Institute, not to the physician		
Gilead Sciences	Grant / Contract	Self
<i>Recipient Name:</i> SARAH CANNON RESEARCH INSTITUTE <i>Grant / Contract Description:</i> RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Gilead Sciences	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> Consulting payment made to institution, Sarah Cannon Research Institute		
<i>Description:</i> CONSULTING SERVICES FOR ADVISORY BOARD OR STEERING COMMITTEE: PAYMENT MADE TO INSTITUTION		
Great Point Partners	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> All payments made to Sarah Cannon Research Institute, not to the physician		
<i>Description:</i> All payments made to Sarah Cannon Research Institute, not to the physician		
Hutchison MediPharma	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> All payments made to Sarah Cannon Research Institute, not to the physician		
<i>Description:</i> All payments made to Sarah Cannon Research Institute, not to the physician		
IGM Biosciences	Grant / Contract	Self
<i>Recipient Name:</i> Sarah Cannon Research Institute <i>Grant / Contract Description:</i> All payments made to Sarah Cannon Research Institute, not to the physician		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research <i>Additional Information:</i> All payments made to Sarah Cannon Research Institute, not to the physician		
Iksuda Therapeutics	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> All payments made to Sarah Cannon Research Institute, not to the physician		
<i>Description:</i> All payments made to Sarah Cannon Research Institute, not to the physician		
Incyte Corporation	Grant / Contract	Self

Recipient Name: SARAH CANNON RESEARCH INSTITUTE Grant / Contract Description: RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE Additional Information:	Recipient Type: Institution Grant / Contract Purpose: Research	
INFINITY PHARMACEUTICALS	Grant / Contract	Self
Recipient Name: SARAH CANNON RESEARCH INSTITUTE Grant / Contract Description: RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE Additional Information:	Recipient Type: Institution Grant / Contract Purpose: Research	
InnoCare Pharma	Consultant	Self
Category: Consultant Additional Information: All payments made to Sarah Cannon Research Institute, not to the physician	Description: All payments made to Sarah Cannon Research Institute, not to the physician	
Janssen Biotech	Grant / Contract	Self
Recipient Name: SARAH CANNON RESEARCH INSTITUTE Grant / Contract Description: RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE Additional Information:	Recipient Type: Institution Grant / Contract Purpose: Research	
Janssen Biotech	Consultant	Self
Category: Consultant Additional Information: All payments made to Sarah Cannon Research Institute, not to the physician	Description: All payments made to Sarah Cannon Research Institute, not to the physician	
Juno Therapeutics	Grant / Contract	Self
Recipient Name: Sarah Cannon Research Institute Grant / Contract Description: All payments made to Sarah Cannon Research Institute, not to the physician	Recipient Type: Institution Grant / Contract Purpose: Research Additional Information: All payments made to Sarah Cannon Research Institute, not to the physician	
Juno Therapeutics	Consultant	Self
Category: Consultant Additional Information: All payments made to Sarah Cannon Research Institute, not to the physician	Description: All payments made to Sarah Cannon Research Institute, not to the physician	
Karyopharm Therapeutics	Grant / Contract	Self
Recipient Name: SARAH CANNON RESEARCH INSTITUTE Grant / Contract Description: RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE Additional Information:	Recipient Type: Institution Grant / Contract Purpose: Research	
KITE	Grant / Contract	Self
Recipient Name: SARAH CANNON RESEARCH INSTITUTE Grant / Contract Description: RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE Additional Information:	Recipient Type: Institution Grant / Contract Purpose: Research	
KITE	Consultant	Self
Category: Consultant Additional Information: Consulting payment made to institution, Sarah Cannon Research Institute	Description: CONSULTANCY: ADVISORY BOARD OR STEERING COMMITTEE PAID TO INSTITUTION	
Loxo	Grant / Contract	Self
Recipient Name: Sarah Cannon Research Institute Grant / Contract Description: All payments made to Sarah Cannon Research Institute, not to the physician	Recipient Type: Institution Grant / Contract Purpose: Research Additional Information: All payments made to Sarah Cannon Research Institute, not to the physician	
Merck	Grant / Contract	Self
Recipient Name: SARAH CANNON RESEARCH INSTITUTE Grant / Contract Description: RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE Additional Information:	Recipient Type: Institution Grant / Contract Purpose: Research	
MORHOSYS	Grant / Contract	Self
Recipient Name: SARAH CANNON RESEARCH INSTITUTE Grant / Contract Description: RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE Additional Information:	Recipient Type: Institution Grant / Contract Purpose: Research	
MorphoSys	Grant / Contract	Self
Recipient Name: Sarah Cannon Research Institute Grant / Contract Description: All payments made to Sarah Cannon Research Institute, not to the physician	Recipient Type: Institution Grant / Contract Purpose: Research Additional Information: All payments made to Sarah Cannon Research Institute, not to the physician	
MorphoSys	Consultant	Self
Category: Consultant Additional Information: All payments made to Sarah Cannon Research Institute, not to the physician	Description: All payments made to Sarah Cannon Research Institute, not to the physician	
Novartis	Grant / Contract	Self

Recipient Name: SARAH CANNON RESEARCH INSTITUTE Grant / Contract Description: RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research
Novartis	Consultant	Self
Category: Consultant Additional Information: All payments made to Sarah Cannon Research Institute, not to the physician		Description: All payments made to Sarah Cannon Research Institute, not to the physician
Nurix Therapeutics	Consultant	Self
Category: Consultant Additional Information: All payments made to Sarah Cannon Research Institute, not to the physician		Description: All payments made to Sarah Cannon Research Institute, not to the physician
Pfizer	Grant / Contract	Self
Recipient Name: SARAH CANNON RESEARCH INSTITUTE Grant / Contract Description: RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research
Pharmacyclics LLC, An AbbVie Company	Grant / Contract	Self
Recipient Name: SARAH CANNON RESEARCH INSTITUTE Grant / Contract Description: RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research
Pharmacyclics LLC, An AbbVie Company	Consultant	Self
Category: Consultant Additional Information: All payments made to Sarah Cannon Research Institute, not to the physician		Description: All payments made to Sarah Cannon Research Institute, not to the physician
Portola Pharmaceuticals	Grant / Contract	Self
Recipient Name: SARAH CANNON RESEARCH INSTITUTE Grant / Contract Description: RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research
Rhizen Pharmaceuticals	Grant / Contract	Self
Recipient Name: Sarah Cannon Research Institute Grant / Contract Description: All payments made to Sarah Cannon Research Institute, not to the physician Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research Additional Information: All payments made to Sarah Cannon Research Institute, not to the physician
Roche	Grant / Contract	Self
Recipient Name: Sarah Cannon Research Institute Grant / Contract Description: All payments made to Sarah Cannon Research Institute, not to the physician Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research Additional Information: All payments made to Sarah Cannon Research Institute, not to the physician
Roche	Consultant	Self
Category: Consultant Additional Information: All payments made to Sarah Cannon Research Institute, not to the physician		Description: All payments made to Sarah Cannon Research Institute, not to the physician
Seattle Genetics	Grant / Contract	Self
Recipient Name: SARAH CANNON RESEARCH INSTITUTE Grant / Contract Description: RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research
Seattle Genetics	Consultant	Self
Category: Consultant Additional Information: Consulting payment made to institution, Sarah Cannon Research Institute		Description: CONSULTANCY: ADVISORY BOARD OR STEERING COMMITTEE PAID TO INSTITUTION
Servier Pharmaceuticals LLC	Consultant	Self
Category: Consultant Additional Information: All payments made to Sarah Cannon Research Institute, not to the physician		Description: All payments made to Sarah Cannon Research Institute, not to the physician
Takeda Oncology	Grant / Contract	Self
Recipient Name: SARAH CANNON RESEARCH INSTITUTE Grant / Contract Description: RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research
Takeda Oncology	Consultant	Self
Category: Consultant Additional Information: All payments made to Sarah Cannon Research Institute, not to the physician		Description: All payments made to Sarah Cannon Research Institute, not to the physician
Teva Pharmaceuticals USA, Inc.	Grant / Contract	Self
Recipient Name: SARAH CANNON RESEARCH INSTITUTE Grant / Contract Description: RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research

TG THERAPEUTICS	Grant / Contract	Self
<i>Recipient Name:</i> SARAH CANNON RESEARCH INSTITUTE <i>Grant / Contract Description:</i> RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
TG THERAPEUTICS	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> Consulting payment made to institution, Sarah Cannon Research Institute		<i>Description:</i> CONSULTANCY: ADVISORY BOARD OR STEERING COMMITTEE PAID TO INSTITUTION
TRILLIUM THERAPEUTICS	Grant / Contract	Self
<i>Recipient Name:</i> SARAH CANNON RESEARCH INSTITUTE <i>Grant / Contract Description:</i> RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Triphase Research & Development Corp.	Grant / Contract	Self
<i>Recipient Name:</i> Sarah Cannon Research Institute <i>Grant / Contract Description:</i> All payments made to Sarah Cannon Research Institute, not to the physician		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research <i>Additional Information:</i> All payments made to Sarah Cannon Research Institute, not to the physician
UNUM THERAPEUTICS	Grant / Contract	Self
<i>Recipient Name:</i> SARAH CANNON RESEARCH INSTITUTE <i>Grant / Contract Description:</i> RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
UNUM THERAPEUTICS	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> All payments made to Sarah Cannon Research Institute, not to the physician		<i>Description:</i> All payments made to Sarah Cannon Research Institute, not to the physician
VERASTEM	Grant / Contract	Self
<i>Recipient Name:</i> SARAH CANNON RESEARCH INSTITUTE <i>Grant / Contract Description:</i> RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
VERASTEM	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> Consulting payment made to institution, Sarah Cannon Research Institute		<i>Description:</i> CONSULTANCY: ADVISORY BOARD OR STEERING COMMITTEE PAYMENT MADE TO INSTITUTION
Vincerox Pharma	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> All payments made to Sarah Cannon Research Institute, not to the physician		<i>Description:</i> All payments made to Sarah Cannon Research Institute, not to the physician
Yingli Pharmaceuticals	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> All payments made to Sarah Cannon Research Institute, not to the physician		<i>Description:</i> All payments made to Sarah Cannon Research Institute, not to the physician

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AbbVie	Other	Self
Category: Other Additional Information:		Description: Honoraria, Consulting Adv Role, Research Funding, Travel, Accomodations, Expenses
Amgen	Other	Self
Category: Other Additional Information:		Description: Honoraria, Consulting Adv Role, Research Funding, Travel, Accomodations, Expenses
AstraZeneca	Other	Self
Category: Other Additional Information:		Description: Honoraria, Consulting Adv Role, Research Funding, Travel, Accomodations, Expenses
Bristol-Myers Squibb	Other	Self
Category: Other Additional Information:		Description: Honoraria, Consulting Adv Role, Research Funding, Travel, Accomodations, Expenses
Celgene	Other	Self
Category: Other Additional Information:		Description: Honoraria, Consulting Adv Role, Research Funding, Travel, Accomodations, Expenses
Celgene	Consultant	Self
Category: Consultant Additional Information:		Description: Honoraria, Consulting Adv Role, Research Funding, Travel, Accomodations, Expenses
Daiichi Sankyo Company	Other	Self
Category: Other Additional Information:		Description: Honoraria, Consulting Adv Role, Research Funding, Travel, Accomodations, Expenses
F. Hoffmann-La Roche	Other	Self
Category: Other Additional Information:		Description: Honoraria, Consulting Adv Role, Research Funding, Travel, Accomodations, Expenses
Gilead Sciences	Other	Self
Category: Other Additional Information:		Description: Honoraria, Consulting Adv Role, Research Funding, Travel, Accomodations, Expenses
Merck	Other	Self
Category: Other Additional Information:		Description: Honoraria, Consulting Adv Role, Research Funding, Travel, Accomodations, Expenses
Merck Sharp and Dohme	Other	Self
Category: Other Additional Information:		Description: Honoraria, Consulting Adv Role, Research Funding, Travel, Accomodations, Expenses
Novartis	Other	Self
Category: Other Additional Information:		Description: Honoraria, Consulting Adv Role, Research Funding, Travel, Accomodations, Expenses
Sandoz Inc.	Other	Self
Category: Other Additional Information:		Description: Honoraria, Consulting Adv Role, Research Funding, Travel, Accomodations, Expenses
Takeda Oncology	Other	Self
Category: Other Additional Information:		Description: Honoraria, Consulting Adv Role, Research Funding, Travel, Accomodations, Expenses

Additional Questions:

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
2. **What is the manuscript title?**
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Novartis	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> Advisory Board		<i>Description:</i> Advisory Board

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AsahiKasei Medical Co.,Ltd.	Grant / Contract	Self
<i>Recipient Name:</i> Tohoku University <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Bristol-Myers Squibb	Other	Self
<i>Category:</i> Other <i>Additional Information:</i>		<i>Description:</i> speaking engagement
Chugai Pharmaceutical	Other	Self
<i>Category:</i> Other <i>Additional Information:</i>		<i>Description:</i> speaking engagement
Chugai Pharmaceutical Co., Ltd.	Grant / Contract	Self
<i>Recipient Name:</i> Tohoku University <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Eisai Co., Ltd.	Grant / Contract	Self
<i>Recipient Name:</i> Tohoku University <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Kyowa Kirin Co., Ltd	Grant / Contract	Self
<i>Recipient Name:</i> Tohoku University <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Novartis	Other	Self
<i>Category:</i> Other <i>Additional Information:</i>		<i>Description:</i> speaking engagement
Sanofi	Other	Self
<i>Category:</i> Other <i>Additional Information:</i>		<i>Description:</i> speaking engagement
Takeda Pharmaceutical Company, Limited	Grant / Contract	Self
<i>Recipient Name:</i> Tohoku University <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Genmab	Data And Safety Monitoring	Other - Honoraria to my institution
<i>Category:</i> Data And Safety Monitoring <i>Additional Information:</i>		<i>Description:</i> Safety Committee
Gilead Sciences	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> Honoraria to my institution		<i>Description:</i>
Incyte Corporation	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Advisory Board. Evaluation Committe for grant application
Nordic Nanovector	Data And Safety Monitoring	Other - Honoraria to my institution
<i>Category:</i> Data And Safety Monitoring <i>Additional Information:</i>		<i>Description:</i> Safety Committee
Novartis	Other	Self
<i>Category:</i> Other <i>Additional Information:</i>		<i>Description:</i> Invited lecturer paid by Novartis, Advisory board
Roche Health Solutions Inc.	Consultant	Other - Honoraria to my institution
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Advisory Board
Takeda Oncology	Consultant	Other - Honoraria to my institution
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Advisory Board

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Efficacy and Safety of Tisagenlecleucel Versus Standard of Care in Adult Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Entity	Type	Interest Held By
Bristol Myers Squibb Company <i>Category: Consultant</i> <i>Additional Information:</i>	Consultant	Self
<i>Description: CAR-T cell therapy advice</i>		
Gilead Sciences <i>Category: Other</i> <i>Additional Information:</i>	Other	Self
<i>Description: Advisory Board</i>		
Janssen Global Services, LLC <i>Category: Consultant</i> <i>Additional Information:</i>	Consultant	Self
<i>Description: CAR-T cells and CLL, Myeloma</i>		
Miltenyi Biotec <i>Category: Other</i> <i>Additional Information:</i>	Other	Self
<i>Description: Advisory Board</i>		
Novartis <i>Category: Consultant</i> <i>Additional Information:</i>	Consultant	Self
<i>Description: Consultant for CAR-T Cell Development</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Gilead Sciences	Travel	Self
<i>Location(s):</i> <i>Additional Information:</i>		<i>Purpose:</i>
Janssen Biotech	Other	Self
<i>Category: Other</i> <i>Additional Information:</i>		<i>Description: Scientific Advisory Board</i>
Janssen Biotech	Travel	Self
<i>Location(s):</i> <i>Additional Information:</i>		<i>Purpose:</i>
Novartis	Other	Self
<i>Category: Other</i> <i>Additional Information:</i>		<i>Description: Scientific Advisory Board</i>
Takeda Oncology	Other	Self
<i>Category: Other</i> <i>Additional Information:</i>		<i>Description: Scientific Advisory Board</i>
Takeda Oncology	Travel	Self
<i>Location(s):</i> <i>Additional Information:</i>		<i>Purpose:</i>

Additional Questions:

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
2. **What is the manuscript title?**
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AbbVie	Grant / Contract	Other - Kyushu University
<i>Recipient Name:</i> Koji Kato <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
AstraZeneca	Grant / Contract	Other - Kyushu University
<i>Recipient Name:</i> Koji Kato <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Bristol-Myers Squibb	Grant / Contract	Other - Kyushu University
<i>Recipient Name:</i> Koji Kato <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Chugai Pharmaceutical Co., Ltd.	Grant / Contract	Other - Kyushu University
<i>Recipient Name:</i> Koji Kato <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Daiichi Sankyo Company LTD	Grant / Contract	Other - Kyushu University
<i>Recipient Name:</i> Koji Kato <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Eisai Co., Ltd.	Grant / Contract	Other - Kyushu University
<i>Recipient Name:</i> Koji Kato <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Kyowa Kirin Co., Ltd	Grant / Contract	Other - Kyushu University
<i>Recipient Name:</i> Koji Kato <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Novartis	Grant / Contract	Other - Kyushu University
<i>Recipient Name:</i> Koji Kato <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Ono	Grant / Contract	Other - Kyushu University
<i>Recipient Name:</i> Koji Kato <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
- Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Bristol Myers Squibb Company	Other	Self
<i>Category: Other</i> <i>Additional Information:</i>		<i>Description: Compensation for presentation Paid to Institution</i>
Celgene	Other	Self
<i>Category: Other</i> <i>Additional Information: to institution</i>		<i>Description: Scientific Advisory Board</i>
F. Hoffmann-La Roche	Other	Self
<i>Category: Other</i> <i>Additional Information: educational symposium</i>		<i>Description: Speaker fee</i>
Kite Pharma	Grant / Contract	Self
<i>Recipient Name: Amsterdam UMC</i> <i>Grant / Contract Description: Research grant</i> <i>Additional Information:</i>		<i>Recipient Type: Institution</i> <i>Grant / Contract Purpose: Research</i>
Kite Pharma	Consultant	Self
<i>Category: Consultant</i> <i>Additional Information:</i>		<i>Description: advisory board</i>
Kite Pharma	Consultant	Self
<i>Category: Consultant</i> <i>Additional Information:</i>		<i>Description: advisory board</i>
Kite Pharma	Consultant	Self
<i>Category: Consultant</i> <i>Additional Information:</i>		<i>Description: speaker fee educational symposium</i>
Kite Pharma	Other	Self
<i>Category: Other</i> <i>Additional Information:</i>		<i>Description: travel reimbursement investigator meeting</i>
Kite Pharma	Other	Self
<i>Category: Other</i> <i>Additional Information:</i>		<i>Description: Speaker fee</i>
Kite Pharma	Other	Self
<i>Category: Other</i> <i>Additional Information:</i>		<i>Description: speaker fee educational symposium</i>
Kite Pharma	Other	Self
<i>Category: Other</i> <i>Additional Information:</i>		<i>Description: Advisory Board</i>
Kite Pharma	Consultant	Self
<i>Category: Consultant</i> <i>Additional Information:</i>		<i>Description: speaker fee educational symposium</i>
Kite Pharma	Consultant	Other - fee paid to institution
<i>Category: Consultant</i> <i>Additional Information:</i>		<i>Description: advisory board</i>
Kite Pharma	Consultant	Self
<i>Category: Consultant</i>		<i>Description: advisory board</i>

Additional Information:		
Kite Pharma	Consultant	Self
Category: Consultant		Description: speaker fee
Additional Information:		
Kite Pharma	Consultant	Other - fee paid to institution
Category: Consultant		Description: advisory board
Additional Information:		
Kite Pharma	Consultant	Self
Category: Consultant		Description: advisory board
Additional Information: advisory board		
Kite Pharma	Travel	Self
Location(s): New York		Purpose: Advisory Board
Additional Information:		
Miltenyi Biotec	Consultant	Other - fee paid to institution
Category: Consultant		Description: advisory board
Additional Information:		
Miltenyi Biotec	Other	Self
Category: Other		Description: Scientific Advisory Board
Additional Information: to institution		
Novartis Pharma	Other	Self
Category: Other		Description: travel reimbursement investigator meeting
Additional Information:		
Novartis Pharma	Consultant	Self
Category: Consultant		Description: advisory board
Additional Information:		
Novartis Pharma	Consultant	Other - fee paid to institution
Category: Consultant		Description: advisory board
Additional Information:		
Novartis Pharma	Consultant	Self
Category: Consultant		Description: advisory board
Additional Information:		
Novartis Pharma	Consultant	Self
Category: Consultant		Description: speaker fee
Additional Information:		
Takeda Oncology	Consultant	Self
Category: Consultant		Description:
Additional Information: Scientific Advisory Board Fee paid to Institution		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Daiichi Sankyo Company	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Advisory Board/Consultancy

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Amgen	Consultant	Self
Category: Consultant Additional Information:		Description: consultant
Astellas Pharma	Consultant	Self
Category: Consultant Additional Information:		Description: consultant
Bayer	Consultant	Self
Category: Consultant Additional Information:		Description: consultant
BeiGene, Ltd.	Consultant	Self
Category: Consultant Additional Information:		Description: consultant
Bristol-Myers Squibb	Consultant	Self
Category: Consultant Additional Information:		Description: consultant
Celgene	Consultant	Self
Category: Consultant Additional Information:		Description: consultant
Janssen Biotech	Consultant	Self
Category: Consultant Additional Information:		Description: consultant
Merck	Consultant	Self
Category: Consultant Additional Information:		Description: consultant
Novartis	Consultant	Self
Category: Consultant Additional Information:		Description: consultant
Roche Products Limited	Consultant	Self
Category: Consultant Additional Information:		Description: consultant
Takeda Oncology	Consultant	Self
Category: Consultant Additional Information:		Description: consultant

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
- Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Tisagenlecleucel versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16596

Summary of Interests

Entity	Type	Interest Held By
Astellas Pharma	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i>
Bristol-Myers Squibb	Grant / Contract	Self
<i>Recipient Name:</i> joaquin martinez <i>Grant / Contract Description:</i> CNIO <i>Additional Information:</i>		<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research
F. Hoffmann-La Roche	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i>
Janssen Biotech	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i>
Novartis	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i>

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Novartis	Employment	Self
<i>Title:</i> Global Program Clinical Head <i>Additional Information:</i>		<i>Position Description:</i> Executive medical director

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Artiva bio	Consultant	Self
Category: Consultant Additional Information:		Description:
Celgene Corporation	Consultant	Self
Category: Consultant Additional Information:		Description:
CRISPR therapeutics	Consultant	Self
Category: Consultant Additional Information:		Description:
Novartis	Consultant	Self
Category: Consultant Additional Information:		Description:

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AlloVir	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Advisory Board
Bristol-Myers Squibb	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Advisory Board
Kite Pharma, Inc.	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Advisory Board
Novartis	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> speaker

Additional Questions:

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
2. **What is the manuscript title?**
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Gilead Sciences Inc	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Speaker bureau, consultant for Gilead and Kite

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16596

Summary of Interests

Entity	Type	Interest Held By
Anylam Pharmaceuticals <i>Category:</i> Consultant <i>Additional Information:</i> paid to employer	Consultant	Self
<i>Description:</i> advisory committee		
Bristol-Myers Squibb <i>Category:</i> Other <i>Additional Information:</i>	Other	Self
<i>Description:</i> Lecture		
Celgene Corporation <i>Location(s):</i> congress ASH <i>Additional Information:</i>	Travel	Self
<i>Purpose:</i> hospitality		
Gilead Sciences <i>Category:</i> Consultant <i>Additional Information:</i> paid to employer	Consultant	Self
<i>Description:</i> Training to european colleagues		
Johnson & Johnson Health Care Systems Inc. <i>Category:</i> Consultant <i>Additional Information:</i> to employer	Consultant	Self
<i>Description:</i> training AL amyloidosis		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Bristol-Myers Squibb	Other	Self
<i>Category: Other</i> <i>Additional Information:</i>		<i>Description: Advisory Boards</i>
Gilead Sciences	Other	Self
<i>Category: Other</i> <i>Additional Information:</i>		<i>Description: Speaker's Honoaria</i>
Janssen Biotech	Other	Self
<i>Category: Other</i> <i>Additional Information:</i>		<i>Description: Speaker's honoraria</i>
Janssen Biotech	Other	Self
<i>Category: Other</i> <i>Additional Information:</i>		<i>Description: Advisory Board</i>
Novartis	Consultant	Self
<i>Category: Consultant</i> <i>Additional Information: 4 sessions, 1hr each, hourly rate</i>		<i>Description: expert consultancy</i>
Novartis	Other	Self
<i>Category: Other</i> <i>Additional Information: hourly rate</i>		<i>Description: National Advisory Boards 17.12.2020</i>

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AbbVie	Other	Self
<i>Category: Other</i>		<i>Description: advisory board</i>
<i>Additional Information:</i>		
Bristol Myers Squibb Company	Other	Self
<i>Category: Other</i>		<i>Description: advisory boards</i>
<i>Additional Information:</i>		
Epizyme, Inc.,	Other	Self
<i>Category: Other</i>		<i>Description: Advisory board</i>
<i>Additional Information:</i>		
F. Hoffmann-La Roche AG	Consultant	Self
<i>Category: Consultant</i>		<i>Description: consultant on management non hodgkin lymphoma</i>
<i>Additional Information:</i>		
F. Hoffmann-La Roche AG	Expert Witness	Self
<i>Category: Expert Witness</i>		<i>Description: expert testimony</i>
<i>Additional Information:</i>		
F. Hoffmann-La Roche AG	Expert Witness	Self
<i>Category: Expert Witness</i>		<i>Description: expert testimony</i>
<i>Additional Information:</i>		
F. Hoffmann-La Roche AG	Other	Self
<i>Category: Other</i>		<i>Description: advisory boards and scientific lectures</i>
<i>Additional Information:</i>		
Gilead Sciences Inc	Other	Self
<i>Category: Other</i>		<i>Description: advisory board</i>
<i>Additional Information:</i>		
Johnson and Johnson	Other	Self
<i>Category: Other</i>		<i>Description: advisory board and scientific lecture</i>
<i>Additional Information:</i>		
Novartis	Other	Self
<i>Category: Other</i>		<i>Description: advisory board</i>
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Novartis	Employment	Self
<i>Title:</i> Senior Principal Biostatistician <i>Additional Information:</i>		<i>Position Description:</i>

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16596

Summary of Interests

Entity	Type	Interest Held By
Bristol Myers Squibb Company	Other	Self
<i>Category:</i> Other <i>Description:</i> Payment for participation in advisory board. Payment was made directly to my institution. <i>Additional Information:</i> Payment was made directly to my institution (Fiona Stanley Hospital) for research and education only and no payment was made directly to myself.		
Gilead Sciences	Other	Self
<i>Category:</i> Other <i>Description:</i> Participation in advisory board <i>Additional Information:</i> Payment for this role was made directly to my institution (Fiona Stanley Hospital) for education and research purposes. No payment received by myself.		
Novartis	Other	Self
<i>Category:</i> Other <i>Description:</i> Advisory board <i>Additional Information:</i> Payment for this role was made directly to my institution (Fiona Stanley Hospital) and is available for general education and research purposes by the department of haematology. No payment received by myself.		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Tisagenlecleucel Vrsus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16596

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
AbbVie	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i>
AstraZeneca	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i>
BeiGene USA, Inc.	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i>
Celgene Corporation	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i>
Genentech	Grant / Contract	Self
<i>Recipient Name:</i> University of Pennsylvania <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Genentech	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i>
Incyte Corporation	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i>
Janssen Biotech, Inc.	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i>
Legend Biotech	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i>
Loxo Oncology	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i>
Merck	Grant / Contract	Self
<i>Recipient Name:</i> University of Pennsylvania <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Novartis	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i>
Regeneron Pharmaceuticals, Inc.	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i>

Additional Questions:

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
2. **What is the manuscript title?**
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Entity	Type	Interest Held By
Bristol-Myers Squibb Company	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>	<i>Description:</i> Advisory Boards, Continuous Education	
Gilead Sciences Inc	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>	<i>Description:</i> Advisory Boards, Continuous Education	
Janssen Global Services, LLC	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>	<i>Description:</i> Advisory Board	
Merck Sharp & Dohme Corporation	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>	<i>Description:</i> Advisory Boards, Continuous Education	
Novartis Pharma	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>	<i>Description:</i> Advisory Boards, Continuous Education	
SANOFI US SERVICES INC.	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>	<i>Description:</i> Advisory Board, Continuous Education Programs	
Takeda Oncology	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>	<i>Description:</i> Advisory Boards, Continuous Education Program	

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization	Type	Interest Held By
Celgene <i>Category:</i> Consultant <i>Additional Information:</i>	Consultant	Self
<i>Description:</i>		
Gilead Foundation <i>Category:</i> Consultant <i>Additional Information:</i>	Consultant	Self
<i>Description:</i>		
Novartis <i>Category:</i> Consultant <i>Additional Information:</i>	Consultant	Self
<i>Description:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Tisagenlecleucel versus standard of care in second-line aggressive B-cell lymphoma
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
AbbVie	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>	<i>Description:</i> Advisory Board	
ADC Therapeutics	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>	<i>Description:</i> Advisory Board	
Amgen	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>	<i>Description:</i> Advisory Board	
AstraZeneca	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>	<i>Description:</i> Advisory Board	
Bristol-Myers Squibb	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>	<i>Description:</i> Advisory Board	
Genentech	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>	<i>Description:</i> Advisory Board	
Genmab	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>	<i>Description:</i> Advisory Board	
Iksuda Therapeutics	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>	<i>Description:</i> Advisory Board	
Incyte Corporation	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>	<i>Description:</i> Advisory Board	
Janssen Biotech	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>	<i>Description:</i> Advisory Board	
Karyopharm Therapeutics	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>	<i>Description:</i> Advisory Board	
Kite Pharma, Inc.	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>	<i>Description:</i> Advisory Board	
Merck	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>	<i>Description:</i> Advisory Board	
Monta Rosa Therapeutics	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>	<i>Description:</i> Advisory Board	

Morphosys	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Advisory Board
Novartis	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Advisory Board
Umoja Biopharma, Inc.	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Advisory Board

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.